Picture of Jubilant Pharmova logo

JUBLPHARMA — Jubilant Pharmova News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Domino's India franchisee beats Q2 profit estimates as cheaper pizzas help demand (updated)

(Adds background in paragraphs 2, 5 and details on results,
shares in paragraphs 6-9)
       BENGALURU/CHENNAI, Oct 25 (Reuters) - Jubilant FoodWorks
 JUBI.NS , which operates Domino's restaurants in India,
reported a smaller-than-expected 26% fall in quarterly earnings
on Wednesday, helped by its move to cut costs and launch cheaper
pizzas to attract consumers.
        Consumer goods makers and restaurants in India have been
launching more affordable products — with lower input costs — to
keep customers coming back when they are cutting back on
expenses due to the 
    high cost of living
    .
  
     The Indian franchisee of Domino's Pizza  DPZ.N  said its
consolidated net profit fell to 972 million rupees ($11.69
million) for the second quarter ended Sept. 30 from 1.32 billion
rupees a year earlier.
    Analysts, on average, were expecting 772.2 million rupees,
according to data from LSEG.
        Jubilant, which also operates Dunkin' and Popeyes
restaurants, earlier this year launched the world's cheapest
pizza at 49 rupees and followed it up with the roll-out of a new
range of spicy pizzas starting at 179 rupees. 
  
         It also cut costs, 
    including in packaging
    .
  
        "Deployment of multiple levers ... disciplined cost
control more than offset cost inflation," Jubilant, which also
runs Domino's stores in Sri Lanka, Bangladesh and Nepal, said in
an investor presentation.
  
        Revenue from operations climbed 5.2% to 13.69 billion
rupees for the reported quarter.
  
        Shares of Jubilant closed up 0.8% at 529.1 rupees on
Wednesday.
  


($1 = 83.1533 Indian rupees)

 (Reporting by Ashna Teresa Britto in Bengaluru and Praveen
Paramasivam in Chennai; Editing by Sohini Goswami)
 ((AshnaTeresa.Britto@thomsonreuters.com;))

Recent news on Jubilant Pharmova

See all news